Friday, July 10, 2026
🇺🇸 FDA

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly Co.

Eli Lilly and clinical programs — 107 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Eli Lilly and projects

107 ClinicalTrials.gov programs sponsored by Eli Lilly and.

Eli Lilly and has 107 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

107 programs

Clinical programs

Page 1 of 3

  1. 0.9% sodium chloride, Lepodisiran

    Eli Lilly Co.

    Atherosclerotic Cardiovascular Disease Elevated lp(a)

    phase 3 small molecule active

    1 trial

  2. 14V-MC-JAJK

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  3. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial

  4. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial

  5. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  6. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  7. H8H-MC-LAHV

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  8. I3Y-MC-JPCF

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  9. I3Y-MC-JPCM

    Eli Lilly Co.

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  10. I3Y-MC-JPEF

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  11. I4V-MC-JAHU

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  12. I4V-MC-JAHW

    Eli Lilly Co.

    Uveitis

    phase 3 small molecule active

    1 trial

  13. I4V-MC-JAHX

    Eli Lilly Co.

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  14. I4V-MC-JAIP

    Eli Lilly Co.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  15. I4V-MC-JAJJ

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  16. I5T-MC-AACO

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 small molecule active

    1 trial

  17. I6T-MC-AMAX

    Eli Lilly Co.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  18. I6T-MC-AMAY

    Eli Lilly Co.

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  19. I6T-MC-AMBA

    Eli Lilly Co.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  20. I6T-MC-AMCD

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  21. I6T-MC-AMCE

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  22. I8F-MC-GPGN

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  23. I8F-MC-GPHP

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  24. I8F-MC-GPIX

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  25. J1I-MC-GZBO

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  26. J1I-MC-GZBP

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  27. J1I-MC-GZQD

    Eli Lilly Co.

    Overweight, Chronic Low Back Pain (CLBP), Obesity

    phase 3 small molecule active

    1 trial

  28. J2A-MC-GZGW

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  29. J2A-MC-GZPL

    Eli Lilly Co.

    Hypertension

    phase 3 small molecule active

    1 trial

  30. J2A-MC-GZPO

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  31. J2A-MC-GZPR

    Eli Lilly Co.

    Peripheral Arterial Disease

    phase 3 small molecule active

    1 trial

  32. J2A-MC-GZPS

    Eli Lilly Co.

    Urinary Incontinence, Stress

    phase 3 small molecule active

    1 trial

  33. J2A-MC-GZPT

    Eli Lilly Co.

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  34. J2A-MC-GZPW

    Eli Lilly Co.

    Chronic Kidney Disease, Atherosclerosis Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  35. J2G-MC-JZJB

    Eli Lilly Co.

    RET-Mutant Medullary Thyroid Cancer

    phase 3 small molecule active

    1 trial

  36. J2G-MC-JZJC

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  37. J2G-MC-JZJX

    Eli Lilly Co.

    RET fusion-Positive NSCLC

    phase 3 small molecule active

    1 trial

  38. J2J-OX-JZLC

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  39. J2S-MC-GZME

    Eli Lilly Co.

    Alcohol Use Disorder

    phase 3 small molecule active

    1 trial

  40. J2T-MC-KGBT

    Eli Lilly Co.

    Perennial Allergic Rhinitis (PAR)

    phase 3 small molecule active

    1 trial

  41. J2T-MC-KGBU

    Eli Lilly Co.

    Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    phase 3 small molecule active

    1 trial

  42. J3M-MC-JZQB

    Eli Lilly Co.

    Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  43. J3M-MC-JZQH

    Eli Lilly Co.

    Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  44. J3R-MC-YDAF

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  45. J3R-MC-YDAG

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  46. J3R-MC-YDAL

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  47. J3R-MC-YDAO

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  48. J4G-MC-JZVD

    Eli Lilly Co.

    Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Eli Lilly and have?

107 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.